Regenerx Biopharm In
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, develops pharmaceuticals from Thymosin beta 4 (Tß4) for tissue protection, repair, and regeneration. The company is developing RGN-259, a sterile and preservative-free eye drop that has completed Phase 3 clinical trial for the treatment of dry eye syndrome and neurotrophic keratitis. It has strategic partnerships with Lee's Pharmaceu… Read more
Regenerx Biopharm In (RGRX) - Net Assets
Latest net assets as of March 2023: $-3.74 Million USD
Based on the latest financial reports, Regenerx Biopharm In (RGRX) has net assets worth $-3.74 Million USD as of March 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($186.81K) and total liabilities ($3.93 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-3.74 Million |
| % of Total Assets | -2004.35% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 420.7 |
Regenerx Biopharm In - Net Assets Trend (2000–2022)
This chart illustrates how Regenerx Biopharm In's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Regenerx Biopharm In (2000–2022)
The table below shows the annual net assets of Regenerx Biopharm In from 2000 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $-3.45 Million | -54.51% |
| 2021-12-31 | $-2.23 Million | +21.04% |
| 2020-12-31 | $-2.82 Million | -20.68% |
| 2019-12-31 | $-2.34 Million | -5.79% |
| 2018-12-31 | $-2.21 Million | +46.26% |
| 2017-12-31 | $-4.12 Million | +32.15% |
| 2016-12-31 | $-6.07 Million | +10.02% |
| 2015-12-31 | $-6.74 Million | -293.83% |
| 2014-12-31 | $-1.71 Million | -5.61% |
| 2013-12-31 | $-1.62 Million | -58.46% |
| 2012-12-31 | $-1.02 Million | -139.58% |
| 2011-12-31 | $-427.00K | -111.82% |
| 2010-12-31 | $3.61 Million | -2.48% |
| 2009-12-31 | $3.70 Million | -19.45% |
| 2008-12-31 | $4.60 Million | -25.29% |
| 2007-12-31 | $6.15 Million | -62.14% |
| 2006-12-31 | $16.25 Million | +131.81% |
| 2005-12-31 | $7.01 Million | +158.80% |
| 2004-12-31 | $2.71 Million | +195.42% |
| 2003-12-31 | $917.00K | +195.81% |
| 2002-12-31 | $310.00K | +1450.00% |
| 2001-12-31 | $20.00K | -92.16% |
| 2000-12-31 | $255.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Regenerx Biopharm In's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11221716800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $108.77 Million | % |
| Total Equity | $-3.45 Million | 100.00% |
Regenerx Biopharm In Competitors by Market Cap
The table below lists competitors of Regenerx Biopharm In ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
VR Factory Games SA
WAR:VRF
|
$449.69 |
|
Woodbois Ltd
LSE:WBI
|
$449.72 |
|
CQS Natural Resources Growth and Income plc
LSE:CYN
|
$449.82 |
|
Santa Rosa Resources Corp
V:STR-H
|
$450.78 |
|
Okmin Resources, Inc.
OTCQB:OKMN
|
$448.65 |
|
Eden Hotel Lanka PLC
CM:EDENN0000
|
$448.34 |
|
Loud Beverage Group Inc
PINK:LBEV
|
$447.52 |
|
Pri0r1ty Intelligence Group PLC
LSE:PR1
|
$446.95 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Regenerx Biopharm In's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -2,229,879 to -3,445,471, a change of -1,215,592.
- Net loss of 1,727,455 reduced equity.
- Other factors increased equity by 511,863.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.73 Million | -50.14% |
| Other Changes | $511.86K | +14.86% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Regenerx Biopharm In's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-0.04 | $0.00 | x |
| 2018-12-31 | $-0.02 | $0.00 | x |
| 2019-12-31 | $-0.02 | $0.00 | x |
| 2020-12-31 | $-0.02 | $0.00 | x |
| 2021-12-31 | $-0.02 | $0.00 | x |
| 2022-12-31 | $-2.40 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Regenerx Biopharm In utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2250.43%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (40.82%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 408.24% | 0.00% | 0.00x | 1.96x | $1.02 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.58 Million |
| 2015 | 0.00% | -8695.44% | 0.17x | 0.00x | $-4.60 Million |
| 2016 | 0.00% | 245.56% | 0.11x | 0.00x | $835.78K |
| 2017 | 0.00% | 505.70% | 0.25x | 0.00x | $698.12K |
| 2018 | 0.00% | -2861.55% | 0.25x | 0.00x | $-1.77 Million |
| 2019 | 0.00% | -1829.35% | 0.11x | 0.00x | $-1.17 Million |
| 2020 | 0.00% | -1984.56% | 0.14x | 0.00x | $-1.24 Million |
| 2021 | 0.00% | -2081.47% | 0.06x | 0.00x | $-1.37 Million |
| 2022 | 0.00% | -2250.43% | 0.20x | 0.00x | $-1.38 Million |
Industry Comparison
This section compares Regenerx Biopharm In's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Regenerx Biopharm In (RGRX) | $-3.74 Million | 408.24% | N/A | $449.00 |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |